Artisan Partners Limited Partnership purchased a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 58,300 shares of the biopharmaceutical company’s stock, valued at approximately $1,399,000.
A number of other institutional investors and hedge funds have also recently made changes to their positions in NKTR. Janus Henderson Group PLC purchased a new stake in Nektar Therapeutics during the 2nd quarter valued at $34,661,000. PointState Capital LP boosted its position in Nektar Therapeutics by 281.7% during the 2nd quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock valued at $33,841,000 after buying an additional 1,277,500 shares during the period. State Street Corp boosted its position in Nektar Therapeutics by 11.3% during the 2nd quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after buying an additional 447,023 shares during the period. Numeric Investors LLC boosted its position in Nektar Therapeutics by 2,111.5% during the 2nd quarter. Numeric Investors LLC now owns 440,729 shares of the biopharmaceutical company’s stock valued at $8,616,000 after buying an additional 420,800 shares during the period. Finally, Vanguard Group Inc. boosted its position in Nektar Therapeutics by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock valued at $273,893,000 after buying an additional 401,914 shares during the period. 96.04% of the stock is owned by institutional investors and hedge funds.
Nektar Therapeutics (NKTR) opened at $51.92 on Wednesday. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $55.42.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.16. The company had revenue of $152.90 million during the quarter, compared to analyst estimates of $126.50 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. Nektar Therapeutics’s quarterly revenue was up 321.2% compared to the same quarter last year. During the same period last year, the business earned ($0.32) EPS. equities analysts forecast that Nektar Therapeutics will post -0.75 EPS for the current fiscal year.
Several equities research analysts have weighed in on NKTR shares. Roth Capital set a $33.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. BidaskClub lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Zacks Investment Research lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Evercore ISI assumed coverage on shares of Nektar Therapeutics in a report on Thursday, August 17th. They issued an “in-line” rating and a $20.00 price objective for the company. Finally, Jefferies Group restated a “buy” rating and issued a $23.00 price objective on shares of Nektar Therapeutics in a report on Friday, August 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $35.58.
In related news, Director Christopher A. Kuebler sold 4,000 shares of the stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $21.86, for a total value of $87,440.00. Following the completion of the transaction, the director now directly owns 40,500 shares in the company, valued at approximately $885,330. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert Chess sold 6,400 shares of the stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $21.72, for a total transaction of $139,008.00. Following the completion of the transaction, the director now owns 274,223 shares of the company’s stock, valued at $5,956,123.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 858,094 shares of company stock valued at $22,868,634. 5.44% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2017/12/06/58300-shares-in-nektar-therapeutics-nktr-acquired-by-artisan-partners-limited-partnership.html.
Nektar Therapeutics Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.